And when a patient is in need of addiction treatment services, they can readily provide available options.” “Not only will they be able to quickly access information critical to the well-being of their patients, they now have the ability to communicate and collaborate with other medical professionals to ensure patients are receiving the best possible care without being placed at risk. “For the physicians and pharmacists serving on the front lines of the addiction crisis, this new technology helps them carry out their responsibilities faster, more efficiently, and with deeper patient insight,” said Sharon M. Practitioners can also use the NarxCare platform to search for addiction treatment providers in proximity to a patient’s address and to access opioid-related educational materials, which can be printed out and given to patients at the time of a visit. The NarxCare platform also facilitates collaboration and coordination of patient care by enabling direct messaging - including the transmission of documents - among the prescribers and pharmacists who use the NJ PMP, and by allowing users to include “care notes” that add critical patient information to the platform such as history of overdose, specific medication restrictions, caregiver support, and other relevant clinical or social information. The program automatically provides “clinical alerts” notifying practitioners when a patient’s safety may be at risk, such as when a patient is obtaining or filling CDS prescriptions from multiple prescribers and pharmacies, is receiving daily morphine levels that exceed limits recommended by the Centers for Disease Control and Prevention (“CDC”), is being prescribed opioid and benzodiazepine medications simultaneously, or has been receiving opioid medications for more than 90 consecutive days. The NarxCare platform makes that job easier by aggregating and analyzing prescription information from providers and pharmacies and presenting the information in color-coded graphics that provide an instant, easy-to-read “visual snapshot” of a patient’s CDS history. New Jersey law requires prescribers and pharmacists to review a patient’s prescription history prior to prescribing and dispensing highly addictive opioid pain medications and other CDS that, when used in conjunction with opioids, can place patients at a higher risk of fatal overdoses. "It is yet another tool as we work to end addiction and save lives." “We're using the latest technology to fight the opioid crisis, and that includes our new NarxCare platform," said Attorney General Grewal. The recently launched “NarxCare” platform is the latest NJ PMP enhancement paid for with funds from the $100 million that the Murphy Administration committed to combatting the opioid epidemic in FY2019. New Jersey prescribers and pharmacists can now track patients’ use of controlled dangerous substances (“CDS”) on a new NJ PMP platform that automatically examines the data on file, analyzes it, and generates an interactive, patient-centered report with visual enhancements – including patient risk alerts – to ensure that patients are not being overprescribed opioid pain medications that can lead to addiction, overdose, and death. Grewal, the Division of Consumer Affairs, and the New Jersey Coordinator for Addiction Responses and Enforcement Strategies ("NJ CARES") today announced enhancements to the NJ Prescription Monitoring Program (“NJ PMP”) that make it easier for prescribers and pharmacists to identify and manage patients at risk for controlled substance abuse and misuse. New “NarxCare” Platform Includes Prescriber-to-Prescriber Messaging System and Other Technology to Better Coordinate Patient Care AG Grewal Announces Enhancements to NJ PMP that Automatically Analyze Patient CDS History and Identify, Flag Potential Addiction Risks
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |